This article is more than 5 years old. Information may no longer be current.

Abbott completes Visiogen acquisition

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

ABBOTT PARK, Ill. — Abbott has completed the acquisition of Visiogen for $400 million in cash, adding the private eye care company to its ophthalmic holdings, a press release from the company announced.

"Visiogen immediately provides Abbott Medical Optics with a talented team of dedicated professionals and an entry point into the accommodating IOL market," Jim Mazzo, senior vice president of AMO, said in the release. "The innovative Synchrony accommodating IOL expands our diverse portfolio of cataract treatments and allows Abbott the opportunity to help the more than 1 billion people worldwide suffering from presbyopia."

Abbott will now be able to market and sell the Synchrony accommodating IOL in Europe, where it has been available commercially since January. The lens is currently under review by the U.S. Food and Drug Administration for approval.